Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 20/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 18/20 | 1.00 |
| ▸ | PDE6D | O43924 | 1/20 | 0.60 |
| ▸ | PDE6A | P16499 | 1/20 | 0.60 |
| ▸ | PDE6G | P18545 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
| ▸ | PDE6B | P35913 | 1/20 | 0.60 |
| ▸ | PDE6C | P51160 | 1/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14361873 | 0.91 | PDE2A (0.83) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL3322584 | 0.91 | PDE2A (0.83) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL14361839 | 0.88 | PDE2A (0.78) | PDE2APDE10A | |
| SCHEMBL12502817 | 0.86 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL12502100 | 0.86 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL14764901 | 0.85 | PDE2A (0.78) | PDE2APDE10APDE4D | |
| SCHEMBL14764974 | 0.85 | PDE2A (0.81) | PDE2APDE10APDE4D | |
| SCHEMBL12502622 | 0.85 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL971396 | 0.83 | PDE2A (0.71) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL14359712 | 0.83 | PDE2A (0.82) | PDE2APDE10APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2670754-B1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-24 | — | — | EP | claimed |
| WO-2013034755-A1 | TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | claimed |
| EP-2670754-B1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-24 | — | — | EP | disclosed |
| EP-2670754-B1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-9540379-B2 | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9540379-B2 | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9540379-B2 | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| EP-2670754-A1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | Boehringer Ingelheim International GmbH (DE) | 2013-12-11 | — | — | EP | disclosed |
| WO-2013034755-A1 | TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034755-A1 | TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | disclosed |
| US-20120302564-A1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOCREA GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302564-A1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOCREA GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302564-A1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOCREA GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| WO-2012104293-A1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302564-A1 | (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | PDE3A, PDE4A, PDE2A | PDE2A 3/4885PDE10A 22/4885PDE6D 31/4885 |
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | PDE2A, PDE12, PDE5A | PDE2A 1/4885PDE10A 10/4885PDE6D 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.